ThyroidApplication of boron neutron capture therapy to the treatment of anaplastic thyroid carcinoma: current status and future perspectivesPisarev, Mario Aa,b; Dagrosa, Maria A; Juvenal, Guillermo JaAuthor Information aNuclear Biochemistry Division, Department of Radiobiology, National Atomic Energy Commission, Argentina and bDepartment of Human Biochemistry, University of Buenos Aires School of Medicine, Buenos Aires, Argentina Correspondence to Mario A. Pisarev, Department of Radiobiology, CNEA, Avenue del Libertador 8250, Buenos Aires 1429, Argentina Tel: +54 11 6772 7184; fax: +54 11 6772 7188; e-mail: [email protected] Sponsorship: Supported by grants from the Argentine National Research Council, State Secretary of Science and Techonology (SECYT), and the University of Buenos Aires Current Opinion in Endocrinology & Diabetes: October 2005 - Volume 12 - Issue 5 - p 352-355 doi: 10.1097/01.med.0000178269.16988.b1 Buy Metrics Abstract Purpose of review Undifferentiated thyroid carcinoma (anaplastic thyroid carcinoma) is an aggressive tumor with a poor prognosis. Experimental data are collected to support the expansion to undifferentiated thyroid carcinoma of boron neutron capture therapy. Recent findings Boron neutron capture therapy has been applied to glioblastoma and melanoma. Studies of boron neutron capture therapy in a human anaplastic thyroid carcinoma cell line in vitro and in tumor-bearing nude mice have shown that uptake of 10B compounds can be fostered that is sufficient to cause tumor growth arrest, cell death, or both. There is preferential uptake of boron compounds by tumor cells compared with noncancerous cells. Additional preclinical information is required about the biodistribution of candidate boron compounds in humans and about possible adverse effects of boron neutron capture therapy on critical nonthyroidal structures of the neck. Summary Boron neutron capture therapy has promise as a management tool for aggressive cancers, including undifferentiated thyroid carcinoma, that are not responsive to conventional radiotherapy or chemotherapy. © 2005 Lippincott Williams & Wilkins, Inc.